is the generic ingredient in two branded drugs marketed by Haleon Us Holdings and is included in one NDA. Additional information is available in the individual branded drug profile pages.
Summary for chlorpheniramine maleate; ibuprofen; phenylephrine hydrochloride
US Patents:
0
Tradenames:
2
Applicants:
1
NDAs:
1
US Patents and Regulatory Information for chlorpheniramine maleate; ibuprofen; phenylephrine hydrochloride
Well-established regulatory pathway; FDA market approval is not required for generics.
Ibuprofen
Patent expiration in most markets since early 2000s.
Generic market dominance; regulatory barriers are minimal.
New formulations (e.g., fast-release, topical) can offer differentiated market entry points.
Phenylephrine Hydrochloride
Patents expired or are close to expiration in key markets.
Challenges exist due to regulatory scrutiny over efficacy and safety—FDA has questioned phenylephrine’s oral efficacy as a decongestant.
Potential for reformulation or alternative delivery methods to extend marketability.
How are competitive and pricing pressures shaping the market?
High commoditization for all three active ingredients due to widespread generic manufacturing.
Price erosion has been significant; for example, generic ibuprofen prices declined by over 30% over the past five years.
Raw material costs, especially for phenylephrine and chlorpheniramine, have also impacted margins.
What are the key innovation and differentiation factors?
Limited scope for innovation due to the age of these compounds.
Differentiation may arise from formulation improvements, such as sustained-release tablets, combined formulas, or alternative delivery routes.
Regulatory approval for new formulations or indications can open niche markets.
What are the strategic investment considerations?
Market maturity: All three active ingredients operate in mature markets with high generic penetration.
Pricing outlook: Downward pricing pressure continues; investments should focus on process efficiency and cost control.
Supply stability: Geopolitical risks in raw material sourcing require diversification strategies.
Regulatory landscape: Changes in regulatory policies, especially concerning efficacy claims for phenylephrine, could impact future sales.
Patent expiration: No significant patent protections remain; R&D investments should target formulation or delivery innovations for differentiation.
Summary table of key factors
Ingredient
Market Size (2023)
CAGR (2023-2028)
Patent Status
Major Raw Material Risks
Key Use/Indication
Chlorpheniramine Maleate
$650 million
4.1%
Expired domestically
Raw material supply disruptions from China
Allergic rhinitis, cold remedies
Ibuprofen
$3.2 billion
3.5%
Expired
Feedstock shortages, price competition
Pain, fever, inflammation
Phenylephrine Hydrochloride
$850 million
2.8%
Expiring/Expired
Price volatility of commodity chemicals
OTC decongestant
Key takeaways
The global markets for chlorpheniramine maleate, ibuprofen, and phenylephrine hydrochloride are mature with modest growth.
Patent expirations have intensified generic competition, applying downward pressure on prices.
Raw material supply chain risks, especially for phenylephrine and chlorpheniramine, demand supply diversification strategies.
Innovation focus centers on formulation improvements and delivery methods rather than new chemical entities.
Regulatory environments may influence future market dynamics, notably for phenylephrine.
Frequently Asked Questions
What are the main drivers of growth for these ingredients?
Growing demand for OTC cold and allergy medications sustains steady market volumes. Market penetration in emerging markets also contributes to growth.
Are there significant regulatory hurdles for expanding use?
For generic formulations, regulatory entry is relatively straightforward. However, reformulations or new indications require approval, especially if efficacy data are contested (e.g., phenylephrine).
How might raw material price fluctuations affect investment returns?
Exposure to commodity chemicals introduces cost volatility. Vertical integration or raw material sourcing diversification can mitigate risks.
What opportunities exist for differentiation?
Development of controlled-release formulations, combination therapies, or alternative delivery methods can unlock niche markets.
What should investors monitor regarding patent status and regulation?
Patent expirations signal market commoditization; regulatory scrutiny, especially of efficacy claims, can influence future sales.
Sources:
[1] MarketsandMarkets, "OTC Drugs Market," 2023.
[2] Grand View Research, "NSAID Market," 2023.
[3] U.S. Food and Drug Administration, "Drug Approvals and Regulation," 2023.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
